Breaking News Instant updates and real-time market news.

LULU

lululemon

$60.13

0.79 (1.33%)

, NKE

Nike

$52.67

-1.03 (-1.92%)

08:48
09/28/17
09/28
08:48
09/28/17
08:48

lululemon CEO says retail alive as people 'crave human connections', CNBC says

Lululemon (LULU) CEO Laurent Potdevin said he does not believe brick-and-mortar retail will fade as "people continue to crave human connections," CNBC reports, citing an interview. Potdevin noted the weakness in other athletic retailer such as Nike (NKE) but said lululemon is different as it does not deal in footwear and it has roughly 2,500 brand ambassadors across communities to foster human engagement and assist the company in keeping its "finger on the pulse." Reference Link

LULU

lululemon

$60.13

0.79 (1.33%)

NKE

Nike

$52.67

-1.03 (-1.92%)

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

LULU lululemon
$60.13

0.79 (1.33%)

09/26/17
BERN
09/26/17
NO CHANGE
BERN
Survey respondents more likely to buy Nike for fashion/function, says Bernstein
Bernstein analyst Jamie Merriman says he and his firm surveyed 1000 people in the U.S. in July, asking them about 22 athletic apparel and footwear brands. At the athletic apparel and footwear category level, 58% of survey respondents expect to spend about the same amount on the category as they have spent over the last 12 months, while 28% expect to spend more and 14% expect to spend less, he notes. Among those who had shopped the brands in the LTM, the analyst says theintention to purchase more in the NTM was similar across Nike (NKE), adidas (ADDYY) and Under Armour (UAA), while Lululemon (LULU) customers reported the highest intention to purchase more going forward. Additionally, Merriman said respondents were most likely to purchase Nike, relative to other brands, for a combination of fashion and function.
09/19/17
WELS
09/19/17
DOWNGRADE
Target $13
WELS
Underperform
Under Armour downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Tom Nikic downgraded Under Armour (UAA) to Underperform and cut his price target for the shares to $13 from $17. With consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now," Nikic tells investors in a research note. The analyst believes the trend change away from performance has left Under Armour "offsides" from a fashion perspective. Further, he notes that unlike Nike (NKE), Under Armour still generates most of its revenue in North America, where the athletic space is seeing much more pressure. The stock's valuation "still appears quite lofty," Nikic argues. The analyst lowered his estimates for Nike, Under Armour, lululemon (LULU) and Finish Line (FINL), but downgraded only Under Armour.
09/12/17
BERN
09/12/17
INITIATION
Target $66
BERN
Market Perform
lululemon initiated with a Market Perform at Bernstein
Bernstein analyst Jamie Merriman started lululemon with a Market Perform rating and $66 price target.
09/05/17
09/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying concerns over potential dilution from the BAMTech stake and the streaming apps are "widely overdone." 2. Patterson-UTI (PTEN) upgraded to Overweight from Neutral at JPMorgan with analyst Sean Meakim saying the 26% selloff since July 19 has created a buying opportunity. 3. lululemon (LULU) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser citing improved product mix, momentum carrying into the third quarter and inventory flow to stores that is finally supporting consumer engagement. 4. U.S. Steel (X) upgraded to Buy from Neutral at BofA/Merrill with analyst Timna Tanners saying the U.S. premium to Chinese prices has fallen to just about $75/ton, half the leves he considers "normal" and expects HRC can "surge toward $700/ton by year end. 5. Prologis (PLD) upgraded to Buy from Hold at SunTrust with analyst Ki Bin Kim citing valuation and several positive catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NKE Nike
$52.67

-1.03 (-1.92%)

09/27/17
MSCO
09/27/17
NO CHANGE
Target $62
MSCO
Overweight
Nike pullback after earnings a 'buy low' opportunity, says Morgan Stanley
Morgan Stanley analyst Jay Sole said he is more bullish on Nike (NKE) after the company revealed with its Q1 report that its new Air VaporMax took top U.S. market share in the high-end price category, implying it outsold Adidas' (ADDYY) "vaunted" Ultra Boost. He also noted that Nike plans to re-implement its MAP pricing policy and is pulling back from unhealthy distribution channels, which he views as "courageous and arguably unexpected steps" that give some explanation for its weak North American guidance. The analyst, who lowered his FY18 EPS estimate by 4% and cut his price target to $62 from $64, keeps an Overweight rating on Nike and contends the post-earnings weakness is an excellent chance to "buy low."
09/27/17
BOFA
09/27/17
NO CHANGE
Target $42
BOFA
Underperform
Nike risk/reward still unfavorable, says BofA/Merrill
Following Nike's Q1 report and lowered guidance, BofA/Merrill analyst Robert Ohmes expects management to lower its previous $50B revenue target for FY20 closer to his forecast of $40B at its October 25 Investor Day. The analyst continues to view Nike's risk/reward as unfavorable and reiterated his Underperform rating given the challenging North American promotional environment, an extended period of revenue decline and further downward estimates revisions, elevated inventory levels globally, and a growth outlook that relies on improving China momentum and a reacceleration in direct-to-consumer engagement.
09/27/17
JEFF
09/27/17
NO CHANGE
Target $48
JEFF
Hold
Jefferies still not a buyer of Nike after Q1 beat
Jefferies analyst Randal Konik attributes Nike's beat in Q1 to low expectations, cost cuts and share repurchases. Inventories are elevated, gross margin declined and North America sales were down as market share is being lost, Konik tells investors in a post-earnings research note titled "Not A Buyer On Cost Cut Beat. Share Losses, Wholesale Exposure Remain Problems." The analyst trimmed his price target on the shares to $48 from $49 and says he's not a buyer post the results. Konik has a Hold rating on the name.
09/27/17
PIPR
09/27/17
NO CHANGE
Target $50
PIPR
Overweight
Piper 'unimpressed' by Nike's quarter, trims price target to $50
Piper Jaffray analyst Erinn Murphy trimmed her price target for Nike shares to $50 from $53 following the company's Q1 results. The analyst says she's "unimpressed" that demand creation, down 18% in Q1, was what "made" the number against an in line sales and lower than expected gross margin result. She adds that the inventory versus sales spread widened quarter-over-quarter by over 700 basis points. Management on the call also set Q2 expectations well below the Street, a familiar trend of late, Murphy writes in a post-earnings research note partially titled "Q1 Results Don't Provide Much Confidence In The Medium Term." The analyst reiterates a Neutral rating on Nike.

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.